Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 20

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 discussion
and analysis contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Please see
Part II, Item 1A. Risk Factors for a discussion of certain risk factors applicable to our business, financial condition, and results of
operations. Operating results are not necessarily indicative of results that may occur for the full year or any other future period.

Any forward-looking statements in this Quarterly Report
reflect our views and assumptions only as of the date that this Quarterly Report. Future events or our future financial performance involves
known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by these forward-looking statements.  Given these
uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation
to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

We qualify all of our forward-looking statements by
these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

About Mosaic

We are a development-stage biotechnology company focused
on advancing and eventually commercializing immunotherapies for the treatment of cancer. We have historically advanced early-stage product
candidates and we are pursuing new product candidates and platforms to build a new pipeline based on our understanding of immunotherapies.

As part of our strategy, on April 26, 2024, we entered
into a binding term sheet (“Binding Term Sheet”) with Oncotelic Therapeutics, Inc.(“Oncotelic”) pursuant to which
we intend to acquire (i) certain rights to Oncotelic’s clinical stage necroptosis cancer therapies associated with its vascular
disruptive agents (“VDAs”) and related regulatory and clinical packages, and (ii) non-exclusive access to its proprietary
Artificial Intelligence (“AI”) technologies for identifying immunotherapy combinations, in exchange for shares of our common
stock valued at $15.0 million upon execution of the definitive agreement, or a combination of common stock and preferred stock to be determined
by the parties, along with additional milestones allowing Oncotelic to earn up to an additional $15.0 million in shares of common stock
that would be valued at the time of issuance,